New Triple-Drug attack shows promise against tough cancers
NCT ID NCT04708470
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 36 times
Summary
This study tests a combination of three drugs (entinostat, PDS01ADC, and bintrafusp alfa) in adults with advanced cancers linked to HPV or certain colon cancers that haven't responded to standard treatments. The goal is to find a safe dose and see if the treatment can shrink tumors. Participants receive treatment for up to 2 years, with follow-up visits and phone check-ins afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.